MIRNA THERAPEUTICS, INC.

Address

2150 WOODWARD ST
AUSTIN, TX, 78744-1038

Information

DUNS: 805509424
# of Employees: N/A

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. A New MicroRNA-1291 Replacement Therapy for Pancreatic Cancer Disease

    Amount: $224,996.00

    DESCRIPTION (provided by applicant): Pancreatic cancer is the fourth leading cause of cancer-related death in the United States. There is a clear need for more effective therapies to treat deadly panc ...

    STTRPhase I2014Department of Health and Human Services
  2. Therapeutic miRNAs in combination with conventional chemotherapy

    Amount: $299,999.00

    DESCRIPTION (provided by applicant): Mirna Therapeutics, a Texas-based company, is developing non-small cell lung cancer (NSCLC) therapies using tumor suppressor miRNAs. This approach, miRNA replace ...

    SBIRPhase I2012Department of Health and Human Services
  3. Systemic delivery of chitosan/miRNA nanoparticles to prostate tumors

    Amount: $299,999.00

    DESCRIPTION (provided by applicant): MicroRNAs (miRNAs) have emerged as a promising new class of therapeutics for cancer. miRNAs are small, non-coding RNAs that determine cell fate by post-transcripti ...

    SBIRPhase I2012Department of Health and Human Services
  4. MicroRNA therapeutics for prostate cancer

    Amount: $282,967.00

    DESCRIPTION (provided by applicant): Prostate cancer (PrCa) is the most commonly diagnosed cancer in men and the second leading cause of cancer deaths in males, following only lung cancer. Despite adv ...

    SBIRPhase I2010Department of Health and Human Services
  5. Development of modified microRNA therapeutics

    Amount: $287,270.00

    DESCRIPTION (provided by applicant): Experimental evidence accumulated in the past few years indicates that several miRNAs likely function as tumor suppressors and that the altered expression of these ...

    SBIRPhase I2010Department of Health and Human Services
  6. Combination molecular therapeutics for lung cancer

    Amount: $171,527.00

    DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer deaths in the United States with an estimated gt160,000 deaths and gt200,000 newly diagnosed cases each year. Despite th ...

    SBIRPhase I2008Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government